Ulrich Freudensprung
AuthID: R-00G-J2Y
1
TITLE: Overall survival (OS) in the IMELDA randomized phase III trial of maintenance bevacizumab (BEV) with or without capecitabine (CAP) for HER2-negative metastatic breast cancer (mBC)
AUTHORS: Joseph Gligorov; Jose Bines; Emilio Alba; Giorgio Mustacchi; Saverio Cinieri; Vineet Gupta; Jean Yves Pierga; Hakan Bozcuk; Rabab Gaafar; Sudeep Gupta; Guillermo Lopez Vivanco; Xiaojia J Wang; Romulo Costa; Kadri Altundag; Ewa Chmielowska; Sabine de Ducla; Ulrich Freudensprung; Paulo Cortes; Dinesh Doval;
PUBLISHED: 2015, SOURCE: 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium in CANCER RESEARCH, VOLUME: 75, ISSUE: 9
AUTHORS: Joseph Gligorov; Jose Bines; Emilio Alba; Giorgio Mustacchi; Saverio Cinieri; Vineet Gupta; Jean Yves Pierga; Hakan Bozcuk; Rabab Gaafar; Sudeep Gupta; Guillermo Lopez Vivanco; Xiaojia J Wang; Romulo Costa; Kadri Altundag; Ewa Chmielowska; Sabine de Ducla; Ulrich Freudensprung; Paulo Cortes; Dinesh Doval;
PUBLISHED: 2015, SOURCE: 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium in CANCER RESEARCH, VOLUME: 75, ISSUE: 9
INDEXED IN: WOS CrossRef
2
TITLE: Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial Full Text
AUTHORS: Joseph Gligorov; Dinesh Doval; Jose Bines; Emilio Alba; Paulo Cortes; Jean Yves Pierga; Vineet Gupta; Romulo Costa; Stefanie Srock; Sabine de Ducla; Ulrich Freudensprung; Giorgio Mustacchi;
PUBLISHED: 2014, SOURCE: LANCET ONCOLOGY, VOLUME: 15, ISSUE: 12
AUTHORS: Joseph Gligorov; Dinesh Doval; Jose Bines; Emilio Alba; Paulo Cortes; Jean Yves Pierga; Vineet Gupta; Romulo Costa; Stefanie Srock; Sabine de Ducla; Ulrich Freudensprung; Giorgio Mustacchi;
PUBLISHED: 2014, SOURCE: LANCET ONCOLOGY, VOLUME: 15, ISSUE: 12